On Risk Estimation versus Risk Stratification in Early Prostate Cancer

English version České info

In a Perspective article, Sigrid Carlsson and Michael Kattan discuss Gnanapragasam and colleagues’ accompanying research study on refining risk stratification in early prostate cancer.

Vyšlo v časopise: On Risk Estimation versus Risk Stratification in Early Prostate Cancer. PLoS Med 13(8): e32767. doi:10.1371/journal.pmed.1002100
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002100

Souhrn

In a Perspective article, Sigrid Carlsson and Michael Kattan discuss Gnanapragasam and colleagues’ accompanying research study on refining risk stratification in early prostate cancer.

Zdroje

1. Lowrance WT, Scardino PT. Predictive models for newly diagnosed prostate cancer patients. Rev Urol 2009;11:117–126. 19918337

2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974. 9749478

3. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005;173:1126–1131. 15758720

4. Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012;80:1075–1079. doi: 10.1016/j.urology.2012.07.040 22995570

5. Sternberg IA, Vela I, Scardino PT. Molecular Profiles of Prostate Cancer: To Treat or Not to Treat. Annu Rev Med 2016;67:119–135. doi: 10.1146/annurev-med-060413-112226 26515982

6. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843–848. 11744442

7. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;101:878–887. doi: 10.1093/jnci/djp122 19509351

8. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol 2016;69:428–435. doi: 10.1016/j.eururo.2015.06.046 26166626

9. Gnanapragasam V, Lophatananon A, Wright K, Muir K, Gavin A, et al. Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. PLoS Med. 2016;e1002063.

10. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526–532. 17405997

11. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–771. 9605647

12. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002;20:82–88. 12012293

13. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010;58:687–700. doi: 10.1016/j.eururo.2010.07.034 20727668

14. Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate cancer. Version 3. 2016 Available: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

15. Kent M, Penson DF, Albertsen PC, Goodman M, Hamilton AS, et al. Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Med 2016;14:25. doi: 10.1186/s12916-016-0572-z 26860993